source
- London biotech Oyster raises $60 million to develop tau-targeting protein degradersOyster Therapeutics, a London-based biotech, announced it has secured $60 million in an extension of its Series A financing round. The funding will support its lead program that uses a modified pr…
- Experts warn AI health advice may be accurate yet lead to poorer outcomesArtificial intelligence now answers hundreds of millions of health questions each week, with tools like ChatGPT fielding queries from the public at an unprecedented scale. Government officials and…